As most breast cancers in men are estrogen-receptor positive, tamoxifen is generally the standard adjuvant therapy and is also recommended as an initial treatment for metastatic hormone receptor-positive breast cancer [29, 31, 32]. The gene discussed is NR4A1; the disease is breast cancer.